Tirzepatide for Cannabis Use Disorder

This trial tests a new method to help people reduce cannabis use with a medication called Tirzepatide, which has shown potential in curbing cravings. Researchers combine this medicine with Motivational Enhancement Therapy to determine its effectiveness in treating Cannabis Use Disorder (CUD), a condition where cannabis use disrupts daily life. The trial is open to adults who regularly use cannabis and seek help to cut down. Participants should have a Body Mass Index (BMI) of 22 or higher and meet specific criteria for CUD severity. As a Phase 3 trial, this treatment represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking therapy.

Research has shown that tirzepatide is generally safe for people. Although the FDA has not yet approved it for treating substance use disorders, it is approved for managing type 2 diabetes, indicating a well-understood safety profile for that condition. Studies have found that tirzepatide can help reduce alcohol consumption, suggesting it might also help with cravings. While specific studies on its use for cannabis use disorder are lacking, early results from related trials indicate it is safe when used in recommended doses.¹²³⁴⁵

Tirzepatide is unique because it targets both the GLP-1 and GIP receptors, which are involved in regulating appetite and energy balance. Unlike standard treatments for cannabis use disorder, which often focus on behavioral therapy and support, Tirzepatide offers a novel approach by potentially reducing cravings through a dual mechanism of action. Researchers are excited about this treatment because it could offer a new, pharmacological option for managing cannabis use disorder, providing hope for those who haven't found success with existing therapies.

Studies have shown that Tirzepatide can help reduce alcohol consumption, suggesting it might also assist with other addictions like Cannabis Use Disorder (CUD). Tirzepatide affects specific parts of the body that control cravings and substance use, similar to its role in managing overeating and alcohol use. Although researchers are still gathering direct evidence of Tirzepatide's effectiveness for CUD, its ability to reduce alcohol cravings is promising. This trial will provide all participants with Tirzepatide alongside psychotherapy over a 12-week treatment period, potentially helping people with CUD by lowering their cannabis use.¹³⁴⁶⁷